|
. .  
|
Faculty
Research InterestsMolecular profiling of ovarian epithelial tumors using Affymetrix gene chip and proteomics technologies - Identification and characterization of molecular markers of ovarian carcinomas - Identification of novel genes amplified in ovarian carcinomas - Evaluation of the role of Wnt/beta-catenin/Tcf pathway defects in the pathogenesis of ovarian endometrioid adenocarcinomas - Identification of genes involved in cervical cancer progression EducationSept 1976- May 1980 Yale University, New Haven, Connecticut; B.A. (Chemistry) Aug 1980-May 1984 Vanderbilt University School of Medicine, Nashville, Tennessee; M.D. Postgraduate TrainingJuly 1984-June 1985 Intern, Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland July 1985-June 1987 Assistant Resident, Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland July 1987-June 1988 Chief Resident, Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland July 1988-June 1990 Clinical Fellow, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland July 1988-Nov 1991Research Fellow, Laboratory of Bert Vogelstein, The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland Honors and Awards1980 B.A., magna cum laude, with distinction in Chemistry, Yale University. 1980 Howard Douglass Moore Prize for excellence in the field of Chemistry, Yale University. 1983 Alpha Omega Alpha, Vanderbilt University School of Medicine. 1984 Janet M. Glasgow Memorial Achievement Citation, Vanderbilt University School of Medicine. 2000 American Society for Clinical Investigation 2000 American Association of University Pathologists Recent PublicationsWu, R., Zhai, Y., Fearon, E.R., and Cho, K.R. Diverse Mechanisms of bβ -catenin Deregulation in Ovarian Endometrioid Adenocarcinomas. Cancer Research 61:8247-8255, 2001. Zhai, Y., Wu, R., Schwartz, D.R., Darrah, D., Kolligs,F.T., Nieman, M.T., Fearon E.R., and Cho, K.R. Role of b-catenin/TCF Regulated Genes in Ovarian Endometrioid Adenocarcinomas. American Journal of Pathology 160:1229-38, 2002. Kolligs, F.T., Nieman, M.N., Winer, I., Hu, G., van Mater, D.S., Feng, Y., Smith, I.M., Wu, R., Zhai, Y., Cho, K.R., and Fearon, E.R. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with b-catenin defects and promotes neoplastic transformation. Cancer Cell, 1:145-155, 2002. Schwartz, D.R., Kardia, S.L.R., Shedden, K.A., Kuick, R., Michailidis, G., Taylor, J.M.G., Misek, D.E., Wu, R., Zhai,Y., Darrah, D.M., Reed, H., Ellenson, L.H., Giordano, T.J., Fearon, E.R., Hanash, S.M., and Cho, K.R. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Research 62:4722-4729, 2002. Shedden, K.A., Kshirsagar, M.P., Schwartz, D.R., Wu, R., Yu, H., Misek, D.E., Hanash, S., Katabuchi, H., Ellenson, L.H., and Cho, K.R. Histological type, organ of origin, and Wnt pathway status: Impact on gene expression profile in ovarian and uterine carcinomas. Clinical Cancer Research 11:2123-31, 2005. ZhuY, WuR, SanghaN, ChoKR, SheddenK, KatabuchiH, and Lubman DM. Classification of ovarian cancer tissues by proteomic patterns. Proteomics 6:584656, 2006. Feng Y, Bommer GT, Zhai Y, Akyol A, Hinoi T, Winer I, Lin HV, Cadigan KM, Cho KR, and Fearon ER. Drosophilasplit ends homologue SHARP functions as a positive regulator of Wnt/b-catenin/T-cell factor signaling in neoplastic transformation. Cancer Res 67:482-91, 2007. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, and Cho KR. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/b-catenin and PI3K/Pten signaling pathways. Cancer Cell 11:321-33, 2007. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, MacDougald OA, Cho KR, and Fearon ER. p53-mediated activation of miRNA34 candidate tumor suppressor genes. Current Biology, 17:1298-307, 2007. Hinoi T, Akyol A, Theisen BK, Ferguson DO, Greenson JK, Williams BO, Cho KR, and Fearon, ER. Mouse model of colonic adenoma-carcinoma progression based on somatic apc inactivation. Cancer Res 67:9721-30, 2007. Zhai Y, Kuick R, Nan B, Ota I, Weiss SJ, Trimble CL, Fearon ER, and Cho KR. Gene expression analysis of pre-invasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res, 67:10163-72, 2007. Wang SS, Smiraglia DJ, Wu Y-Z, Ghosh S, Rader JS, Cho KR, Bonfiglio TA, Nayar R, Plass C, Sherman ME. Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning (RLGS). Cancer Research, 68:2489-97, 2008. Kim H, Wu R, Cho KR, Thomas DG, Gossner G, Liu JR, Giordano TJ, Shedden KA, Misek DE, Lubman DM. Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas. Proteomics- Clinical Applications, 2:571-584, 2008. Sangha N, Wu R, Kuick R, Powers S, Mu D, Fiander D, Yuen K, Katabuchi H, Tashiro H, Fearon ER, and Cho KR. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia 10:1362-72, 2008. Cho KR and Shih IeM. Ovarian Cancer. Annual Review of Pathology, 4:287-313, 2009. Bommer GT, Feng Y, Ira A, Giordano TJ, Kuick R, Kadikoy H, Sikorski D, Wu R, Cho KR, Fearon ER.IRS1 regulation by Wnt/beta-catenin signaling and varied contribution of IRS1 to the neoplastic phenotype. 2J Biol Chem, 2010 Jan 15;285(3):1928-38. Epub 2009 Oct 20. CVs from interested candidates can be forwarded to kathcho@umich.edu Additional Lab LinksLab MembersRon Wu, Assistant Research Professor
|
||||||
|
|||||||
